VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis
The Journal of Pharmacology and Experimental Therapeutics · 2025-01 · 392 (1) · 100006
DOI: 10.1124/jpet.124.002298 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025-01. Verfasst von Shelby Waddell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tubulin Modulators, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Health Science Center, University of Tennessee.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee.
- Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Center for Cancer Research, University of Tennessee Health Science Center, Memphis…
- Genetics and Genomics and Informatics, University of Tennessee Health Science Center, Memphis, Tennessee.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee; Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, M…
Förderung
- NCI NIH HHS
- National Cancer Institute
- Health Science Center, University of Tennessee
- National Institutes of Health
- US Department of Defense
Zitieren
APA
Waddell, S., Zhao, G., Liu, Z., Chen, H., Zhang, W., Wang, Y., Miller, D. D., Yue, J., & Li, W. (2025). VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis. The Journal of Pharmacology and Experimental Therapeutics, 392(1), 100006. https://doi.org/10.1124/jpet.124.002298
Vancouver
Waddell S, Zhao G, Liu Z, Chen H, Zhang W, Wang Y, et al. VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis. The Journal of Pharmacology and Experimental Therapeutics. 2025;392(1):100006. doi:10.1124/jpet.124.002298
BibTeX
@article{Waddell2025,
author = {Waddell, Shelby and Zhao, Guannan and Liu, Ziping and Chen, Hao and Zhang, Wenjing and Wang, Yaohong and Miller, Duane D and Yue, Junming and Li, Wei},
title = {VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2025},
volume = {392},
number = {1},
pages = {100006},
doi = {10.1124/jpet.124.002298}
}
EUVIMED